Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to address the cognitive symptoms that have long remained untreated.

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

“Securing robust patent protection for our proprietary biomarkers is a top priority, and we are pleased to announce the grant of this U.S. patent supporting our MT1988 program for cognitive ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to finally address the cognitive symptoms that have long remained untreated.

Monument Therapeutics announced its partnership with the Foundation for the National Institutes of Health (FNIH) to continue testing and advancing MT1988, a treatment option being developed for ...

The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John ...

Cambridge Cognition’s spin-out company, Monument Therapeutics, has secured a £1.0 million investment to advance its novel schizophrenia treatment, MT1988. This funding is expected to enhance ...